Med-Zenith
- Industry
- Medical Devices
- Founded Year
- 2005
- Headquarters
- Building 2, Yard 3, Middle Jinhang Road, Shunyi District, Beijing, 101316, China
- Employee Count
- 150
Key People
- Jian Meng - Founder
Assessment
- Team
-
Aspect: First-time physician innovator
Summary: Founded by Dr. Jian Meng, a physician innovator.
While Dr. Jian Meng brings valuable medical expertise, the lack of prior MedTech entrepreneurial experience could pose hurdles in product development and commercialization.
- Clinical Need
-
Aspect: Very Strong
Summary: Addresses significant unmet needs in cardiovascular treatments.
Med-Zenith's products, such as the PT-Valve for severe pulmonary regurgitation, cater to substantial unmet needs in cardiovascular care, indicating a strong market demand.
- Competition
-
Aspect: Very crowded + Strategics
Summary: Operates in a highly competitive market with major players.
Med-Zenith faces intense competition from well-established firms like Edwards Lifesciences and Medtronic, which dominate the cardiovascular device sector.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing innovative cardiovascular devices presents moderate technical challenges.
While Med-Zenith's products involve innovative designs, the technical challenges are manageable with appropriate expertise and resources.
- Patent
-
Aspect: Strong
Summary: Holds a robust patent portfolio with 33 granted patents.
With 33 granted patents, Med-Zenith demonstrates a commitment to innovation and intellectual property protection, enhancing its market position.
- Financing
-
Aspect: Medium
Summary: Secured funding from multiple investors, indicating moderate financial health.
Med-Zenith's funding from investors like Gage Finance, KPCB China, and CTS Capital suggests a reasonable financial foundation, though details on funding amounts are limited.
- Regulatory
-
Aspect: 510k/PMA
Summary: Achieved regulatory approvals for key products.
Med-Zenith's PT-Valve received innovation approval from the CFDA, indicating compliance with regulatory standards and facilitating market entry.
Opportunity Rollup
- Odds of Success
- 3.35
- Peak Market Share
- 5.1
- Segment CAGR
- 15.1%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Transcatheter Heart Valves
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.26 |
| 2 | 0.76 |
| 3 | 1.78 |
| 4 | 3.57 |
| 5 | 5.10 |
Key Takeaway
Med-Zenith's innovative cardiovascular devices address significant clinical needs but face challenges from intense competition and regulatory hurdles.